Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > SOST


Brief Information

Target Synonym:Sclerostin,UNQ2976/PRO7455/PRO7476,SOST,Sclerosteosis,DAND6,SOST1,VBCH,CDD
Number of Launched Drugs:1
Number of Drugs in Clinical Trials:3
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data


Immobilized Human LRP-6 (20-630), Mouse IgG2a Fc Tag (Cat. No. LR6-H5253) at 5 μg/mL (100 μL/well) can bind Biotinylated Human SOST, His Tag, primary amine labeling (Cat. No. SOT-H8245) with a linear range of 0.005-0.313 μg/mL (QC tested).


Immobilized Cynomolgus SOST, His Tag (Cat. No. SOT-C5246) at 5 μg/mL (100 μL/well) can bind Biotinylated Human LRP-6, His,Avitag (Cat. No. LR6-H82E7) with a linear range of 0.005-0.156 μg/mL (QC tested).

Synonym Name



Sclerostin (SOST) is also known as Sclerosteosis, VBCH, is a secreted glycoprotein with a signal peptide for secretion and a C-terminal cysteine knot-like (CTCK) domain and belongs to the Cerberus/DAN family of bone morphogenetic protein (BMP) antagonists. Sclerostin is produced by the osteocyte and has anti-anabolic effects on bone formation. More recently Sclerostin has been identified as binding to LRP5/6 receptors and inhibiting the Wnt signalling pathway. Wnt pathway inhibition under these circumstances is antagonistic to bone formation (meaning Sclerostin antagonizes bone formation). It has been shown that SOST binds BMP-5, -6, and -7 with high affinity and BMP-2 and -4 with low affinity. Sclerostin production by osteocytes is inhibited by parathyroid hormone, mechanical loading and cytokines including oncostatin M, cardiotrophin-1 and leukemia inhibitory factor. Sclerostin production is increased by calcitonin. Thus, osteoblast activity is self regulated by a negative feedback system. Mutations of Sclerostin is associated with the syndrome Sclerosteosis, and reduced sclerostin expression results in a milder form of the disorder called van Buchem disease.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Romosozumab AMG-785; CDP-7851 Approved Evenity, EVENITY Japan Osteoporosis Amgen Inc 2019-01-08 Osteoporosis; Bone Diseases, Metabolic; Osteoporosis, Postmenopausal; Osteogenesis Imperfecta; Fractures, Bone Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
Setrusumab UX143; NOV-3; MOR-05813; BPS-804 Phase 3 Clinical Morphosys Ag, Novartis Pharma Ag Osteoporosis; Bone Diseases, Metabolic; Hypophosphatasia; Osteogenesis Imperfecta; Renal Insufficiency, Chronic Details
Resugosbart SHR-1222 Phase 1 Clinical Jiangsu Hengrui Medicine Co Ltd, Suzhou Suncadia Biopharmaceuticals Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd Osteoporosis; Osteoporosis, Postmenopausal Details
Blosozumab LY-2541546; TST002; TST-002 Phase 1 Clinical Eli Lilly And Company Osteoporosis; Osteoporosis, Postmenopausal Details

This web search service is supported by Google Inc.

Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
+1 888-377-6111
1 Innovation Way, Newark, DE 19711, USA

Leave a message